CCL5 and plasma cell myeloma: In addition, maraviroc is being studied in clinical trials in breast, colorectal, and pancreatic cancer and Kaposi’s sarcoma58 following studies revealing that CCL5 and/or CCR5 are overexpressed in many cancers (including breast, gastrointestinal, prostatic, melanoma, Hodgkin lymphoma, and multiple myeloma), and they promote tumor growth, extracellular matrix remodeling, angiogenesis, immune and stromal cell recruitment, and immunosuppressive polarization of macrophages58.